Inclusion Criteria:

• * Aged 50 years or older; women must be post-menopausal
• * Chronic kidney disease stage 3 or 4 (estimated glomerular filtration rate with the 4 CKD-EPI 2021 race-free equation: 20-59 mL/min/1.73m\^2; stable renal function in the past 3 months)
• * History of inadequately controlled hypertension (systolic blood pressure 120-159 mmHg on two separate days) and on a stable antihypertensive regimen for the past 6 weeks
• * Weight stable in the prior 3 months (\<5% weight change) and willing to remain weight stable throughout the study
• * Ability to provide informed consent

Exclusion Criteria:

• * Patients with advanced chronic kidney disease requiring chronic dialysis
• * Significant pulmonary disorders including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma
• * History of spontaneous pneumothorax, collapsed lung due to traumatic injury that has not fully healed, burst eardrum that has not fully healed, or other conditions of the eardrum
• * Significant co-morbid conditions with a life expectancy of \< 1 year
• * History of severe congestive heart failure (i.e., ejection fraction \<35%)
• * History of hospitalization within the last month
• * Albuminuria (albumin to creatinine ratio \> 2200 mg/g
• * Current smoker
• * Immunosuppressant agents taken in the past 12 months. Steroids used for the treatment of gout are acceptable; however, patients should not be using steroids within 2 weeks (or 14 days) prior to the vascular testing (rationale: may confound vascular testing)
• * Known malignancy
• * Inability to cooperate with or clinical contraindication for magnetic resonance imaging including: severe claustrophobia, implants, devices, or non-removable body piercings (these individuals can participate in the study but are excluded from the MRI procedure)
• * Illicit drug use or alcohol dependence/abuse, which in the opinion of the investigators, would prohibit compliance with the study intervention